- Home
- GNTA vs MAIA Comparison
GNTA vs MAIA Comparison
Compare GNTA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- MAIA
- Stock Information
- Founded
- GNTA 2014
- MAIA 2018
- Country
- GNTA Italy
- MAIA United States
- Employees
- GNTA N/A
- MAIA N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- MAIA Health Care
- Exchange
- GNTA Nasdaq
- MAIA Nasdaq
- Market Cap
- GNTA 81.2M
- MAIA 46.7M
- IPO Year
- GNTA 2021
- MAIA 2022
- Fundamental
- Price
- GNTA N/A
- MAIA $1.82
- Analyst Decision
- GNTA Strong Buy
- MAIA
- Analyst Count
- GNTA 1
- MAIA 0
- Target Price
- GNTA $25.00
- MAIA N/A
- AVG Volume (30 Days)
- GNTA 29.4K
- MAIA 549.7K
- Earning Date
- GNTA 01-01-0001
- MAIA 08-08-2025
- Dividend Yield
- GNTA N/A
- MAIA N/A
- EPS Growth
- GNTA N/A
- MAIA N/A
- EPS
- GNTA N/A
- MAIA N/A
- Revenue
- GNTA N/A
- MAIA N/A
- Revenue This Year
- GNTA N/A
- MAIA N/A
- Revenue Next Year
- GNTA N/A
- MAIA N/A
- P/E Ratio
- GNTA N/A
- MAIA N/A
- Revenue Growth
- GNTA N/A
- MAIA N/A
- 52 Week Low
- GNTA $2.74
- MAIA $1.40
- 52 Week High
- GNTA $7.28
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- GNTA 54.55
- MAIA 53.36
- Support Level
- GNTA $2.74
- MAIA $1.60
- Resistance Level
- GNTA $3.94
- MAIA $2.03
- Average True Range (ATR)
- GNTA 0.29
- MAIA 0.12
- MACD
- GNTA 0.08
- MAIA 0.02
- Stochastic Oscillator
- GNTA 88.33
- MAIA 58.14
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.